Fox Chase Cancer Center
BCRL Home
Mission Statement
Milestones
Mentoring and Training Program
Biographies & Scientific Staff
Collaborators
Publications
Fox Chase Cancer Center Home
BCRL Home » Research Projects » Breast Cancer Therapy by Differentiation Gene Activation

Breast Cancer Therapy by Differentiation Gene Activation

References
Breast Cancer Therapy by Differentiation Gene Activation

  1. Greenlee, R.T., Hill-Harmon, M.B., Murray, T., Thun, M.  Cancer Statistics, 2001.  CA Cancer J Clin.  51, 15-36, (2001).
  2. Jemal, A., Thomas, A., Murray, T., Thun, M. Cancer Statistics, 2002, CA Cancer J Clin., 52, 23-47,( 2002).
  3. Forbes JF.  The incidence of breast cancer: the global burden, public health considerations.  Semin Oncol.  24 (1 Suppl 1), S1-20-S1-35, (1997).
  4. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst., 93, 824-842. (2001).
  5. Mirza, A.N., Mirza, N.Q., Vlastos, G., Singletary, S.E.  Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.  Ann. Surg. 235, 10-26, (2002).
  6. Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. Chem Res Toxicol., 14, 767-90, (2001).
  7. Matsumoto, H., Yamane, T. Green Tea and Cancer Prevention. J. Women’s Cancer, 2, 153-158, (2000).
  8. Dunn, B.K., McCaskill-Stevens, W., Kramer, B., Ford, L.G. Chemoprevention of breast cancer: The NSABP’s breast cancer prevention trial.  J. Women’s Cancer, 2,  177-191, (2000).
  9. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA, 286,  2251-2256, (2001).
  10. Lynch HT, Casey MJ. Current status of prophylactic surgery for hereditary breast and gynecologic cancers. Curr Opin Obstet Gynecol., 13, 25-30, (2001).
  11. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet, 356, 1876-1881, (2000).
  12. Khurana, K.K., Loosmann, A., Numann, P.J., Khan, S.A. Prophylactic mastectomy - Pathologic findings in high-risk patients.  Arch. Pathol. Lab. Med., 124, 378-381, (2000).
  13. Narod S. Prophylactic mastectomy in carriers of BRCA mutations. N Engl J Med., 345, 1498; (2001).
  14. Riggs T.  Prophylactic mastectomy in carriers of BRCA mutations. N Engl J Med., 345, 1499-500, (2001).
  15. Stoutjesdijk MJ, Barentsz JO. Prophylactic mastectomy in carriers of BRCA mutations.  N Engl J Med., 345, 1499, (2001).
  16. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.  J Natl Cancer Inst., 93, 1633-1637, (2001).
  17. McGregor DH, Land CE, Choi K, Tokuoka S, Liu PI, Wakabayashi I, Beebe GW. Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki 1950-1989.  J Natl Cancer Inst 59, 799-811, (1977).
  18. Boice JD Jr, Preston D, Davis FG, Monson RR.  Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiation Research. 125,  214-222, (1991).
  19. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 26, 291-302, (2000).
  20. Cutuli, B., Borel, C., Dhermain, F., Magrini, S.M., Wasserman ,T.H., Bogart, J.A.,  et al. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol 59, 247-255, (2001).
  21. Janov, A.J., Tulecke, M., O'Neill, A., Lester, S., Mauch, P.M., Harris, J., Schnitt, S.J., Shapiro, C.L.  Clinical and Pathologic Features of Breast Cancers in Women Treated for Hodgkin's Disease: A Case-Control Study.  Breast J. 7, 46-52, (2001).
  22. Baum, M.  The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women.  Breast Cancer Research and  Treatment 69, 210, (2001).
  23. Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol., 19,  2596-2606, (2001).
  24. Robertson, J.F., Nicholson, R.I., Bundred, N.J., Anderson, E., Rayter, Z., Dowsett, M., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res, 61,  6739-46, (2001).
  25. Gail, M.H., Brinton, L.A.,, Byar, D.P., Corle, D.K., Breen, S.B., Schairer, C., Mulvihill, J.J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.  J. Natl. Cancer Inst., 81, 1879-1886, (1989).
  26. Trapido, E.J.  Age at first birth, parity and breast cancer risk Cancer 51, 46-948, (1983).
  27. MacMahon, B., Cole, P., Lin, T.M.  et al.  Age at first birth and breast cancer risk.  Bull. Nat’l.  Hlth. Org. 43, 209,(1970).
  28. Chie, W.C., Hsieh, C., Newcomb, P,A., Longnecker, M.P., Mittendorf, R., Greenberg, E.R., Clapp, R.W., Burke, K.P., Titus-Ernstoff, L., Trentham-Dietz, A., MacMahon, B.  Age at any full-term pregnancy and breast cancer risk.  Am J Epidemiol.  151, 715-722, (2000).
  29. Holmberg, E., Holm, L.E., Lundell, M., Mattsson, A., Wallgren, A., Karlsson, P.  Excess breast cancer risk and the role of parity, age at first childbirth and exposure to radiation in infancy.  Br J Cancer 85, 362-366, (2001).
  30. Vessey, M.D., McPherson, K., Roberts, M.M., Neil, A. and Jones, L.  Fertility and the risk of breast cancer.  Br.  J.  Cancer 52, 625-628, (1985).
  31. Kelsey, J.L. and Horn-Ross, P.L. Breast Cancer: Magnitude of the problem and descriptive epidemiology . Epidemiologic Reviews, 15,  7-16, (1993).
  32. Lambe, M., Hsieh, C.C., Chan, H.W., Ekbom, A., Trichopoulos, D. and Adami, H. O. Parity, age at first and last birth, and risk of breast cancer: A population-based study in Sweden.  Breast Cancer Res. Treat. 38,  305-311, (1996).
  33. Russo, I.H. and Russo, J. Chorionic Gonadotropin: A Tumoristatic and Preventive Agent in Breast Cancer, in Drug Resistance in Oncology  (Teicher, B.A., ed.), Marcel Dekker, Inc.,pp. 537-560 (1993).
  34. Russo, I.H., Koszalka, M. and Russo, J.  Human chorionic gonadotropin and rat mammary cancer prevention.  J. Natl. Cancer Inst. 82, 1286-1289, (1990).
  35. Russo, I.H., Koszalka, M., and Russo, J. Effect of human chorionic gonadotropin on mammary gland differentiation and carcinogenesis.  Carcinogenesis 11, 1849-1855, (1990).
  36. Russo, J., Saby, J., Isenberg, W. and Russo, I.H. Pathogenesis of mammary carcinoma induced in rats by 7,12-dimethylbenz(a)anthracene.  J. Natl. Cancer Inst. 59, 435-445,(1977).
  37. Russo, I.H. and Russo, J. Role of hCG and inhibin in breast cancer (Review).  Int. J. Oncol. 4, 297-306, (1994).
  38. Russo, I.H. and Russo, J. Mammary gland neoplasia in long-term rodent studies. Environmental Health Perspectives 104, 938-967,(1996).
  39. Srivastava, P., Russo, J. and Russo, I.H. Chorionic gonadotropin inhibits rat mammary carcinogenesis through activation of programmed cell death.  Carcinogenesis 18, 1799-1808, (1998).
  40. Mgbonyebi, O. P., Tahin, Q., Russo, J. and Russo, I.H. Serum levels of chorionic gonadotropin in treated female rats during the progression of DMBA-induced tumorigenesis.  Proc. Am. Assoc. Cancer Res. 37, 1564a, (1996).
  41. Tahin, Q., Mgbonyebi, O. P., Russo, J. and Russo, I.H. Influence of hormonal changes induced by the placental hormone chorionic gonadotropin on the progression of mammary tumorigenesis.  Proc. Am. Assoc. Cancer Res. 37,  1622a, (1996).
  42. Russo, J and Russo, I.H. Human Chorionic Gonadotropin in Breast Cancer Prevention In:”Endocrine Oncology, (S.P. Ethier, editor), Humana Press Inc., Totowa, NJ., pp121-136 (2000)
  43. Alvarado, M.E., Alvarado, N.E., Russo, J. and Russo, I.H. Human chorionic gonadotropin inhibits proliferation and induces expression of inhibin in human breast epithelial cells in vitro. In Vitro 30A, 4-8, (1994).
  44. Alvarado, M.V., Russo, J. and Russo, I.H. Immunolocalization of inhibin in the mammary gland of rats treated with hCG.  J. Histochem. and Cytochem. 41, 29-34, (1993).
  45. Russo, J., Tay, L.K., and Russo, I.H. Differentiation of the mammary gland and susceptibility to carcinogenesis.  Breast Cancer Res. Treat. 2, 5-37, (1982).
  46. Rao, D.N., Ganesh, B., and Desai, P.B. Role of reproductive factors in breast cancer in a low-risk area: a case-control study.  Br. J. Cancer, 70, 129-152,(1994).
  47. Coe, K.  Breast cancer in Hispanic women. Women and Cancer, 1, 38-43,(1998).
  48. Gaudette, L.A., Silberberg, C., Altmayer, C.A., and Gao, R.N. Trends in breast cancer incidence and mortality.  Health Reports. 8,  29-40, (1996).
  49. Apter, D.  Hormonal events during female puberty in relation to breast cancer risk. Europ. J. Cancer Prev.  5, 476-482,(1996).
  50. Shivvers, S.A., Miller, D.S. Preinvasive and invasive breast and cervical cancer prior to or during pregnancy. [Review].  Clinics in Perinatology, 24, 369-389,(1997).
  51. Russo, J., Wilgus, G. and Russo, I.H. Susceptibility of the mammary gland to carcinogenesis.  I. Differentiation of the mammary gland as determinant of tumor incidence and type of lesion.  Am. J. Pathol. 96, 721-734,(1979).
  52. Russo, J. and Russo, I.H. Influence of differentiation and cell kinetics on the susceptibility of the mammary gland to carcinogenesis.  Cancer Res. 40, 2677-2687, (1980).
  53. Russo, J. and Russo, I.H. Susceptibility of the mammary gland to carcinogenesis.  II.  Pregnancy interruption as a risk factor in tumor incidence.  Am. J. Pathol. 100, 497-512, (1980).
  54. Russo, J. and Russo, I.H. Toward a physiological approach to breast cancer prevention.  Cancer Epidemiol. Biomarkers & Prev. 3, 353-364, (1994).
  55. Russo, J., Rivera, R., and Russo, I.H. Influence of age and parity on the development of the human breast.  Breast Cancer Res. and Treat. 23, 211-218, (1992).
  56. Russo, J. and Russo, I.H. Developmental pattern of the human breast and susceptibility to carcinogenesis.  European J. of Cancer Prevention 2, 85-100, (1993).
  57. Nandi, S., Guzman, R.C., and Yang, J. Hormones and mammary carcinogenesis in mice, rats and humans: a unifying hypothesis.  Proc. Natl. Acad., Sc. USA, 92, 3650-3657,(1995).
  58. Sinha, D.K., Patzik, J.E., and Dao, T.L. Progression of rat mammary development with age and its relationship to carcinogenesis by a chemical carcinogen.  Int. J. Cancer, 31, 321-327, (1983).
  59. Russo, I.H., Koszalka, M., and Russo, J. Comparative study of the influence of pregnancy and hormonal treatment on mammary carcinogenesis.  Brit. J. Cancer, 64, 481-484, (1991).
  60. Russo, I.H. and Russo, J. Role of pregnancy and chorionic gonadotropin in breast cancer prevention, in Proc. IV. European Congress on Menopause. (M.H. Birkhauser and H. Rozenbaum, eds.)  Editions ESKA, Paris,. pp. 133-142. (1998)
  61. Russo, I.H., Russo, J. Developmental stage of the rat mammary gland as determinant of its susceptibility to 7,12-dimethylbenz[al anthracene.  J Natl Cancer Inst 61, 1439, (1978).
  62. Russo, J. Basis of cellular autonomy in susceptibility to carcino­genesis.  Toxicol Pathol. 11,149, (1983).
  63.  Russo, I.H., Pokorzynski, T., Russo, J. Contraceptives as hormone-­preventive agents in mammary carcinogenesis.  Proc. Am. Assoc. Cancer Res. 27, 912a, (1986).
  64. Dao, T.L. Carcinogenesis of mammary gland in rat.  Prog. Exp. Tumor Res .5, 157,(1964).
  65. Russo, J., Russo, I.H. DNA-labeling index and structure of the rat mammary gland as determinants of its susceptibility to carcino­genesis.  J Natl Cancer Inst 61, 1451. (1978).
  66. Dao, T.L, Bock, F.G., Greiner, M.J. Mammary carcinogenesis by 3­methylcholanthrene 11: inhibitory effect of pregnancy and lacta­tion on tumor induction.  J. Natl. Cancer Inst. 25, 991, (1960).
  67. Huggins, C., Grand, L.C., Brillantes, F. Critical significances of breast structure in the induction of mammary cancer in the rat.  Proc. Natl. Acad. Sci. 45, 1294, (1959).
  68. Ciocca, D.R., Parente, A., Russo, J. Endocrinologic milieu and sus­ceptibility of the rat mammary gland to carcinogenesis.  Am. J. Pathol. 109, 74, (1982).
  69. Tay, L.K. and Russo, J.  Metabolism of 7,12-Dimethylbenz(a)anthracene by Rat Mammary Epithelial Cells in Culture.   Carcinogenesis 4, 733-738, (1983).
  70. Russo, J., Tay, L.K., Russo, I.H. Differentiation of the mammary gland and susceptibility to carcinogenesis.  Breast Cancer Res. Treat. 2, 5-75, (1982).
  71. Tay, L.K., Russo, J. 7,12-dimethylbenz [a] anthracene-induced DNA binding and repair synthesis in susceptible and non-susceptible mammary epithelial cells in culture.  J. Natl. Cancer Inst. 67, 155, (1981).
  72. Russo, J., Miller, J., Russo, I.H. Hormonal treatment prevents DMBA-induced rat mammary carcinoma.  Proc. Am. Assoc. Cancer Res. 23, 348a, (1982).
  73. Russo, J., Janssens, J. and Russo, I.H. Recombinant human chorionic gonadotropin (r-hCG) significantly reduces primary tumor cell proliferation in patients with breast cancer. Breast Cancer Research and Treatment.  64, 161a, (2000).
  74. Russo, J., Mailo, D., Hu, Y-F., Balogh, GA.,Sheriff, F., and Russo, I.H. Breast differentiation and its implication in cancer prevention. Clinical Cancer Research. 11, 931s-936s, (2005).
  75. Mailo, D., Russo, J., Sheriff, F., Hu, YF., Tahin, Q., Mihaila, D., Balogh G and Russo, I.H.. Genomic signature induced by differentiation in the rat mammary gland. Proc. Am. Assoc. Cancer Res. 2002
  76. Russo, J. and Russo, I.H. Role of differentiation in the pathogenesis and prevention of breast cancer.  Endocrine Related Cancer 4, 7-21,(1997).
  77. Russo, J. Tahin, Q., Lareef, H.M., Hu, YF. Russo, I.H. Neoplastic transformation of human breast epithelial cells by estrogens and chemical carcinogens. Environmental and Molecular Mutagenesis.  39, 000-000,2002.
  78. Tay, L.K., Russo, J. Formation and removal of 7,12-dimethylbenz [a] anthracene-nucleic acid adducts in rat mammary epithelial cells with different susceptibility to carcinogenesis.  Carcinogenesis 2, 1327, (1981).

Main Publications Originated from this project

  1. Russo, J. and Russo, I.H. A new paradigm in breast cancer prevention. Medical Hypotheses and Research 1:11-22, 2004.
  2. Russo, J., Mailo, D., Hu, Y-F., Balogh, G.A., Sheriff, F. and Russo, I. H. Breast differentiation and its implication in cancer prevention. Clinical Cancer Research 11:931s-936s, 2005.
  3. Russo, J. Balogh, G.A., Chen, J., Fernandez, S.V., Fernbaugh, R., Heulings, R., Mailo, D.A., Moral, R., Russo, P.A., Sheriff, F.A, Vanegas, J.E., Wang, R. and Russo, I.H. The concept of stem cell in the mammary gland and its implication in morphogenesis, cancer and prevention.  Frontiers in Bioscience 11:151-172, 2006.
  4. Russo, I.H., and Russo, J. Primary prevention of breast cancer by hormone-induced differentiation.  In: Cancer Prevention (Eds: H-J, Senn and U. Kapp). Springer, Heidelberg, 2007. Pp111-130.
  5. Russo, J. , Balogh, G., and Russo, I.H. Breast Cancer Prevention.  Climacteric, 10: (Suppl 2) 47 – 53, 2007.

 

Abstracts Publications

    1. Russo, J., Lareef, M.H., Russo, I.H., and Jiang, X. Modulation of Hox gene expression in human breast epithelial cells by human chorionic gonadotropin. Proc. Am. Assoc. Cancer Res. 42:2649a, 2001.
    2. .Guo, S., Russo, I.H., Hu, Y.F., and Russo, J. Comparative analysis of gene expression between epithelial cells from undifferentiated and differentiated lobular structures of the human breast. Proc. Am. Assoc. Cancer Res. 43:2002
    3. Mailo, D., Russo, J., Sheriff, F., Hu, Y.F., Tahin, Q., Mihaila, D., Balogh G and Russo, I.H. Genomic signature induced my differentiation in the rat mammary gland. Proc. Am. Assoc. Cancer Res.43: 5368a, 2002
    4. Russo, I.H., Mailo, D., Srivastava, P., and Russo, J.  Human chorionic gonadotropin (hCG) induces in the virgin rat mammary gland the same genomic signature that is induced by pregnancy. Proc. Am. Assoc. Cancer Res. 44: 3588a, 2003.
    5. Russo, J. and Russo I.H. A new paradigm in the prevention of breast cancer.  In. J. of Mol. Medicine 12: (Supp. 1) 146a, 2003.
    6. Mailo, D., Balogh, G.V., Russo, I.H., and Russo, J. Human chorionic gonadotropin induces differential expression of genes controlling multiple DNA repair pathways in human breast epithelial cells. Proc. Am. Assoc. Cancer Res.45:1550a, 2004.
    7. Wang, R. Russo, J., Balogh, G. A., Mailo, D., Sheriff, F.S., Fernbaugh, R., Russo, P.A. Moral, R. and Russo, I.H The mammary cancer preventive effect of hCG is associated with a specific genomic signature in the rat mammary gland. Proc. Am. Assoc. Cancer Res.46:1578a. 2005.
    8. Mailo, D., Russo, J., Sheriff, F., Balogh, G., Heulings, R. and Russo, Specificity of the Genomic Signature of Human Chorionic Gonadotropin in its Preventive Effect on Mammary Carcinogenesis. Proc. Am. Assoc. Cancer Res.46: 5202a.  2005.
    9. Russo, J and Russo, I.H. The genomic Profile of the Postmenopausal Nulliparous and Parous Breast. CLIMACTERIC, Vol. 8, Suppl.2, Sy24-04,2005
    10. Daniel A. Mailo, Patricia A. Russo, Gabriela A. Balogh, Irma H. Russo, Fathima S. Sheriff, Susan A. Appt, Robert M. Blair,  J. Mark Cline,  and Jose Russo. Human Chorionic Gonadotropin (hCG) Induces Specific Molecular Pathway of Cell Differentiation in the Mammary Gland of Macaca fascicularis.  Proceeding of the Am. Assoc Cancer Res. 47:1424a, 2006.
    11. Russo, I.H., Mufei, L., Fernandez, S.V., and Russo, J. Methylation of the estrogen receptor alpha by pregnancy and human chorionic gonadotropin.  Proceeding of the Am. Assoc. Cancer Res. 47:1595a, 2006.
    12. Daniel A. Mailo, Patricia A. Russo, Gabriela A. Balogh, Irma H. Russo, Fathima S. Sheriff, Susan A. Appt, Robert M. Blair,  J. Mark Cline,  and Jose Russo. Human Chorionic Gonadotropin (hCG) Induces Specific Molecular Pathway of Cell Differentiation in the Mammary Gland of Macaca fascicularis. Proceeding of the Cancer Prevention 2006. St Gallen.
    13. Liu M, Fernandez SV, Russo J, and Russo IH. Estrogen receptor alpha (ERα) Downregulation by Pregnancy and Human Chorionic Gonadotropin (hCG) Treatment is mediated by Methylation.  Proceeding Endocrine Society, 2006.
    14. Johana E. Vanegas, Mehmet Kocdor, Julia S. Pereira, Hilal Kocdor, Jose Russo, Kara Snider, Fathima Sheriff, and Irma H. Russo Preventive effect of hCG on rat mammary carcinogenesis. Proc. International Conference on Gonadotropins and Receptor. 2008
    15. Hilal Kocdor, Mehmet Ali Kocdor, Jose Russo, Johana E. Vanegas, Kara Snider, Fathima Sheriff, Irma H. Russo, Sandra V. Fernandez Human chorionic Gonadotropin (r-hCG) Prevents the Neoplastic Transformation of Human Breast Epithelial Cells by 17 Beta Estradiol. Proc. International Conference on Gonadotropins and Receptor. 2008
    16. Irma H. Russo and Jose Russo Use of hCG in the prevention of breast cancer in young nulliparous women. Proc. International Conference on Gonadotropins and Receptor. 2008